Physician profile
Elizabeth Ramirez
NPI 1285716829
$15,236.54
in general payments reported to CMS, 2019-2025
37 companies · $425 in 2025
The $425 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $333 · 2021: $364 · 2022: $10K · 2023: $3,099 · 2024: $255 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,530 · Travel and Lodging: $1,213 · Education: $1,013 · Gift: $22.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,529.56 |
| Travel and Lodging | $1,212.72 |
| Education | $1,013.35 |
| Gift | $22.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $12,728.34 | 2022-2023 | Da Vinci Surgical System, Davinci Xi |
| Abbvie INC. | $480.10 | 2019-2023 | |
| Glaxosmithkline, LLC. | $298.97 | 2020-2024 | Trelegy Ellipta |
| Daiichi Sankyo INC. | $170.45 | 2020-2022 | |
| Medtronic, INC. | $159.46 | 2024-2025 | Corevalve Evolut R, Truclear |
| Mayne Pharma Commercial LLC | $136.01 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $124.73 | 2025 | Breyanzi |
| Astellas Pharma US INC | $119.58 | 2023-2025 | Veozah |
| Exeltis, USA INC. | $102.15 | 2019-2025 | Slynd |
| Evofem Biosciences, INC. | $93.73 | 2021-2024 | Phexxi |
| Amag Pharmaceuticals, INC. | $66.96 | 2019-2020 | |
| Therapeuticsmd, INC. | $60.60 | 2019-2021 | |
| Scynexis, INC. | $55.67 | 2022 | |
| Hologic Sales and Service, LLC | $55.47 | 2021-2024 | Acessa Provu System |
| Exact Sciences Corporation | $48.59 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $47.07 | 2022-2024 | Twirla |
| Millicent US INC | $44.43 | 2019-2023 | Femring, Intrarosa |
| Coopersurgical, INC. | $43.22 | 2023-2024 | Summit Doppler |
| Pfizer INC. | $34.54 | 2023 | |
| Medtronic USA, INC. | $33.50 | 2019 | |
| Myovant Sciences INC. | $31.94 | 2021-2022 | |
| Avanos Medical | $27.99 | 2019 | |
| Lupin INC. | $27.06 | 2020 | |
| Avion Pharmaceuticals | $26.43 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.70 | 2025 | |
| Dysis Medical, INC. | $20.65 | 2022 | |
| Axogen | $19.00 | 2025 | |
| Covidien LP | $18.30 | 2019 | |
| Organon LLC | $18.26 | 2024 | |
| Sumitomo Pharma America, INC. | $17.00 | 2023 | Myfembree |
| Mission Pharmacal Company | $15.96 | 2021 | |
| Meditrina | $15.45 | 2023 | |
| Lilly USA, LLC | $15.00 | 2019 | |
| Merck Sharp & Dohme LLC | $14.90 | 2021 | |
| Novo Nordisk INC | $13.84 | 2020 | |
| Vertical Pharmaceuticals, LLC | $13.50 | 2019 | |
| Shield Therapeutics INC | $12.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.